U.S. stock futures slip lower; Cook’s firing increases Fed independence worries
CRANBURY, N.J. - Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company trading near its 52-week low of $0.16, has announced the anticipated closure of a public offering that will raise $11.5 million in gross proceeds on Thursday. The funds are aimed at addressing the company’s non-compliance with NYSE American listing standards and supporting the development of its obesity treatment programs. According to InvestingPro analysis, the company’s market capitalization stands at just $4.42 million, with technical indicators suggesting the stock is currently in oversold territory.
The company had been previously notified by NYSE American of its failure to meet the continued listing standards by the end of an 18-month plan period on April 10, 2025. An appeal hearing is scheduled for later this quarter, and while the outcome is uncertain, Palatin is optimistic about meeting the necessary requirements. InvestingPro data reveals the company’s challenging financial position, with an EBITDA of -$30.08 million in the last twelve months and a concerning cash burn rate.
The financing is part of Palatin’s strategic efforts to advance its pipeline of obesity treatments, including novel melanocortin receptor 4 (MC4R) long-acting peptides and oral small molecules. The company plans to submit Investigational New Drug (IND) applications for these candidates in Q4 2025, with initial clinical data expected in the first half of 2026. Phase 1 studies will involve patients with hypothalamic obesity, a condition that can be either acquired or congenital.
In addition to its obesity program, Palatin is also engaging in discussions for potential collaborations and asset sales related to its ocular portfolio. The company is making progress with its Phase 3 dry eye disease program and preclinical glaucoma and retina programs, expecting to execute deals in the second and third quarters of this year.
This news is based on a press release statement and reflects the company’s current expectations regarding its financing and development plans. The forward-looking statements involve risks and uncertainties, and actual results may differ materially from those projected. For a deeper understanding of Palatin’s financial health and future prospects, investors can access comprehensive analysis and 15+ additional ProTips through InvestingPro’s detailed research reports, which provide expert insights on over 1,400 US stocks.
In other recent news, Palatin Technologies, Inc. announced the pricing of a public offering, aiming to raise approximately $11.5 million through common stock and warrants, with the possibility of an additional $11.5 million from warrant exercises. The company plans to use the net proceeds for working capital and the development of its obesity program. In another development, Palatin reported promising results from Phase 3 trials of its dry eye disease treatment, PL9643, which showed significant symptom resolution, suggesting potential commercial success in a market projected to reach $7.46 billion by 2029. Additionally, Palatin’s Phase 2 obesity study demonstrated significant appetite control improvements with its MC4R agonist, bremelanotide, both alone and in combination with tirzepatide.
Meanwhile, Palatin is appealing a delisting notice from NYSE American due to non-compliance with stockholders’ equity requirements, with the appeal process expected to last 60 to 90 days. The company’s stock will continue trading during this period as it explores strategies to strengthen its financial position. Palatin is actively pursuing licensing discussions and equity financing to address listing criteria. The outcome of the appeal will determine the future of its stock listing on the exchange.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.